Will FDA/CMS Parallel Review Idea Make Headway This Time?
Executive Summary
The possibility of simultaneous FDA and CMS evaluations of new health products is back in the front of agency officials' minds after a series of fits and starts over the past several years, says CMS Chief Medical Officer Barry Straube
You may also be interested in...
FDA And CMS Agree To Share Data Routinely In Step Toward Parallel Reviews
A June 23 memorandum of understanding on data sharing could serve as a first step toward parallel reviews by FDA and CMS for marketing approval and Medicare coverage, according to FDA
FDA And CMS Agree To Share Data Routinely In Step Toward Parallel Reviews
A June 23 memorandum of understanding on data sharing could serve as a first step toward parallel reviews by FDA and CMS for marketing approval and Medicare coverage, according to FDA
FDA And CMS Agree To Share Data Routinely In Possible Step Toward Parallel Reviews
Agencies have signed memorandum of understanding for data-sharing, though parallel reviews are "not a done deal."